
At last, a scabies therapy you can trust with your smallest patients.[3]
Learn more about FDA-approved Natroba™ for your practice.
Natroba™
(spinosad) Topical Suspension, 0.9%

Children deserve better.

Twenty-nine percent of all scabies prescriptions in the US are for children under the age of 18 years.[1] The need for an agent with a better pediatric safety profile is long overdue.

29% **of all scabies prescriptions in the US are for children under the age of 18.**

Natroba™ is now available.[2-5]

- No evidence of systemic absorption of the active compound, spinosad
- No neurotoxicity of the active compound, spinosad
- No known resistance challenges associated with current agents used in today's treatment of scabies

Ensure your patients have the opportunity to achieve a "complete cure." Initiate treatment with Natroba™.[3]

Learn more about the safe, effective prescription treatment that has no known published data documenting human mite resistance to the active compound, spinosad.[3]

Visit **natroba.com**

References: 1. IQVIA May 28, 2021. **2.** Data on file, ParaPRO, LLC. **3.** Natroba Prescribing Information. **4.** JAAD clinical article (full citation TBD). **5.** Khalil S et al. *PLos Negl Trop Dis.* 2017:11(11): e0005920.

IMPORTANT SAFETY INFORMATION

INDICATION

Natroba™ Topical Suspension is a scabicide indicated for the topical treatment of scabies infestations in adult and pediatric patients four (4) years of age and older.

ADJUNCTIVE MEASURES

Natroba™ Topical Suspension should be used in the context of an overall lice management program:

- Wash in hot water or dry-clean any bedding, clothing and towels used by anyone having scabies.
- If any member of a household presents with scabies, all household members should be treated with Natroba™ Topical Suspension.

IMPORTANT SAFETY INFORMATION

Natroba™ Topical Suspension contains benzyl alcohol and is not recommended for use in pediatric patients below the age of 4 years. The safety and effectiveness of Natroba™ Topical Suspension have not been established in pediatric patients less than 4 years of age with scabies infestation. Most common adverse events were: application site irritation (3%)* and dry skin (2%).

*Application site irritation also includes application site pain and burning sensation.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

See pocket for Full Prescribing and Patient Information.